Statement on TB and HIV Coinfection Ahead of IAS2019
July 18, 2019—Tuberculosis (TB) is the leading infectious cause of death worldwide and the number one cause of death among
TB Alliance Names Eugene Sun as Senior Vice President for Research and Development
NEW YORK (June 25, 2019)—TB Alliance today announced the appointment of Eugene Sun, MD to the position of Senior Vice
Health 20 Annual Summit will urge G20 Health and Finance Ministers to enforce the necessary marriage between the wealth and the health of nations
The G20’s top health and health financing experts will assemble in Tokyo on the eve of the Osaka G20 heads
New Milestone for Children with Tuberculosis Reached as One Million Treatments of Child-Friendly Medicines are Ordered
SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered
Mitchell Warren Elected President of TB Alliance Stakeholders Association, Joins Board of Directors
NEW YORK (June 12, 2019)—TB Alliance, a not-for-profit organization leading the development of new, improved and affordable tuberculosis (TB) treatments,
FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis
Investigational drug pretomanid, developed by non-profit TB Alliance, is under regulatory review for treatment of extensively drug-resistant tuberculosis and treatment-intolerant
News
German Federal Ministry of Education and Research Invests in New TB Treatments
Every year, more than ten million people worldwide contract tuberculosis (TB) and in 2017, 1.6 million people died as a
Tuberculosis, Among the Oldest Infectious Diseases, Is Now the World’s Deadliest – It’s Time to Invest in Solutions
GENEVA (May 22, 2019) – This week at the Seventy-second World Health Assembly, TB Alliance is joining our partners in global health
New Research on Drug-Resistant TB Treatment Presented at ATS 2019
Two of TB Alliance’s academic collaborators presented findings from scientific research related to drug-resistant forms of tuberculosis at the American Thoracic
TB Alliance and Partners Form Multidisciplinary Center for Translational TB Drug Research
NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center